Dova Pharmaceuticals, Inc. (DOVA) financial statements (2021 and earlier)

Company profile

Business Address 240 LEIGH FARM ROAD
DURHAM, NC 27707
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 10595
Cash and cash equivalents 10595
Receivables 1 
Inventory, net of allowances, customer advances and progress billings 4 
Inventory 4 
Prepaid expense 11
Other undisclosed current assets 2 
Total current assets: 11296
Noncurrent Assets
Property, plant and equipment 00
Total noncurrent assets: 00
TOTAL ASSETS: 11296
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 135
Accounts payable 11
Accrued liabilities 123
Interest and dividends payable 01
Debt 730
Due to related parties 00
Other undisclosed current liabilities  0
Total current liabilities: 1935
Noncurrent Liabilities
Long-term debt and lease obligation 14 
Long-term debt, excluding current maturities 14 
Liabilities, other than long-term debt 2 
Contract with customer, liability2
Total noncurrent liabilities: 16 
Total liabilities: 3635
Stockholders' equity
Stockholders' equity attributable to parent 7661
Common stock 00
Additional paid in capital 206118
Accumulated deficit (129)(57)
Total stockholders' equity: 7661
TOTAL LIABILITIES AND EQUITY: 11296

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Revenues 10 
Cost of revenue
(Cost of Goods and Services Sold)
 (1) 
Gross profit: 9 
Operating expenses (81)(29)
Other undisclosed operating income 1 
Operating loss: (71)(29)
Nonoperating income
(Other Nonoperating income)
 10
Interest and debt expense (2)(1)
Loss before gain (loss) on sale of properties: (72)(30)
Other undisclosed net loss  (0)
Net loss available to common stockholders, diluted: (72)(30)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss: (72)(30)
Comprehensive loss, net of tax, attributable to parent: (72)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: